Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Change in Acquisitions & Divestments: 2019-2025

Historic Change in Acquisitions & Divestments for Crinetics Pharmaceuticals (CRNX) over the last 7 years, with Sep 2025 value amounting to $382.4 million.

  • Crinetics Pharmaceuticals' Change in Acquisitions & Divestments rose 152.98% to $382.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 129.22%. This contributed to the annual value of $575.8 million for FY2024, which is 70.79% up from last year.
  • Crinetics Pharmaceuticals' Change in Acquisitions & Divestments amounted to $382.4 million in Q3 2025, which was up 70.68% from $224.0 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' Change in Acquisitions & Divestments' 5-year high stood at $382.4 million during Q3 2025, with a 5-year trough of $244,000 in Q4 2021.
  • In the last 3 years, Crinetics Pharmaceuticals' Change in Acquisitions & Divestments had a median value of $139.3 million in 2024 and averaged $166.0 million.
  • In the last 5 years, Crinetics Pharmaceuticals' Change in Acquisitions & Divestments tumbled by 98.12% in 2021 and then soared by 28,870.49% in 2022.
  • Over the past 5 years, Crinetics Pharmaceuticals' Change in Acquisitions & Divestments (Quarterly) stood at $244,000 in 2021, then spiked by 28,870.49% to $70.7 million in 2022, then climbed by 22.62% to $86.7 million in 2023, then soared by 112.24% to $184.0 million in 2024, then surged by 152.98% to $382.4 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $382.4 million for Q3 2025, versus $224.0 million for Q2 2025 and $306.5 million for Q1 2025.